RP8: A Potential Drug Target and Biomarker for Disease (G23378)

Target Name: RRP8

NCBI ID: G23378

RRP8

RP8: A Potential Drug Target and Biomarker for Disease

RP8 (NML), also known as Resorcinol, is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell proliferation and has been linked to the development and progression of many diseases, including cancer.

RP8 has been identified as a potential drug target by researchers because of its unique structure and its ability to interact with a variety of different molecules. RP8 is a glycoprotein, which means that it consists of both protein and carbohydrate components. The protein component of RP8 consists of four subunits that are held together by disulfide bonds.

One of the unique features of RP8 is its ability to form a monomeric species, which means that it can exist in a single form. This is important because it allows RP8 to interact with a wide variety of different molecules, including small molecules, peptides, and proteins.

RP8 has been shown to interact with a number of different proteins, including the transcription factor NF-kappa-B and the protein PDGF. This suggests that it may be a good candidate for drugs that are designed to inhibit the activity of these molecules.

In addition to its potential as a drug target, RP8 has also been shown to be a valuable biomarker for the diagnosis and prognosis of a number of different diseases. For example, RP8 has been shown to be elevated in the blood of patients with a variety of different cancers, including breast, lung, and colorectal cancers.

RP8 has also been shown to be elevated in the urine of patients with urological tract cancers, which suggests that it may be a useful diagnostic tool for these conditions.

In addition to its potential as a drug target and biomarker, RP8 is also of interest to researchers because of its unique structure and its ability to interact with a variety of different molecules. These properties make it an attractive candidate for further study, and the research that has been done on RP8 has provided valuable insights into the biology of cell proliferation and the development and progression of disease.

Overall, RP8 is a protein that has the potential to be a drug target or a biomarker for a variety of different diseases. Further research is needed to fully understand its biology and its potential as a therapeutic agent.

Protein Name: Ribosomal RNA Processing 8

Functions: Essential component of the eNoSC (energy-dependent nucleolar silencing) complex, a complex that mediates silencing of rDNA in response to intracellular energy status and acts by recruiting histone-modifying enzymes. The eNoSC complex is able to sense the energy status of cell: upon glucose starvation, elevation of NAD(+)/NADP(+) ratio activates SIRT1, leading to histone H3 deacetylation followed by dimethylation of H3 at 'Lys-9' (H3K9me2) by SUV39H1 and the formation of silent chromatin in the rDNA locus. In the complex, RRP8 binds to H3K9me2 and probably acts as a methyltransferase. Its substrates are however unknown

The "RRP8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RRP8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets